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Background: Aldehyde dehydrogenase 1 (ALDH1) is an important marker of tumor-initiating cells. We aimed to
investigate ALDH1 expression in benign breast disease and human breast cancer of different histologic stages.
Methods: Immunohistochemical staining of ALDH1 was applied to 21 cases with benign breast diseases, 47 ductal
carcinoma in situ (DCIS) cases, 62 cases diagnosed with invasive cancer with extensive intraductal component (EIC),
and 58 cases diagnosed with invasive cancer without EIC.
Results: ALDH1 was expressed in tumor cells in 61.0 % of 164 breast cancer cases, which was higher than that in
benign breast disease (3/21) (P < 0.001). Of these 167 breast cancer cases, a significantly higher rate (54/58) of
intratumoral ALDH1 expression was observed in invasive cancer without EIC cases than that in DCIS cases (19/46,
one case not available) and invasive cancer with EIC cases (27/60, two cases not available) (P < 0.001). Interestingly,
a significantly higher rate (22/48) of intratumoral ALDH1 expression in invasive component was observed than that
in in situ component (7/48) in the same tumor (P = 0.001). In 47 DCIS cases, no significant association was observed
between ALDH1 positivity and any clinicopathological parameter (all P > 0.05). However, ALDH1 positive invasive
breast cancers were significantly more likely to be with large tumor size (P = 0.001), high grade (P < 0.001), and high
Ki67 expression (P = 0.009).
Conclusions: ALDH1 may play an important role in the invasion of breast cancer, and may be associated with
aggressive phenotypes of breast cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1608671725154947.
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Breast cancer is a worldwide malignant disease. Recent
studies [1–3] suggest that this disease is driven by a
subpopulation of breast cancer cells, called breast
tumor-initiating cells (BT-ICs), which have been identi-
fied with the capacity for self-renewal and the ability to
generate different cell types [4]. BT-ICs bear the pheno-
type of CD44+/CD24- [5], and aldehyde dehydrogenase
1 (ALDH1) is also an important marker of BT-ICs [6].
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creativecommons.org/publicdomain/zero/1.0/be a better marker of BT-ICs than CD44+/CD24-in im-
munodeficient mice [6].
Previous studies [1, 6-8] have found ALDH1 positive
cancer cells may be associated with aggressive pheno-
types and poor clinical outcomes in breast cancer pa-
tients. Park and colleagues have attempted to investigate
the role of ALDH1 in the progression of breast cancer
[9]. They have found ALDH1 positive cells were more
frequent in basal-like and HER2+ than in luminal tu-
mors, but no significant difference of ALDH1 expression
was observed in four histologic groups (invasive ductal
carcinoma (IDC), IDC with ductal carcinoma in situ
(DCIS), DCIS with microinvasion, and pure DCIS).
However, the ALDH1-positive rate in IDC seems higher
than that in DCIS in another study [1]. The previousle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ALDH1 in different studies are different [1, 6-9].
Furthermore, the normal mammary stem-like cells can
also be identified by the expression of ALDH1 [10–12].
Isfoss and colleagues have found a positive association be-
tween the frequency of ductular ALDH1 positive cells and
several breast cancer risk factors in histologically normal
breast tissue [12], which supports previous evidence that
ALDH1 may play a role in the development of breast
cancer.
In this study, ALDH1 expression was investigated in
benign breast disease and human breast cancer of differ-
ent histologic stages (DCIS, invasive cancer with exten-
sive intraductal component (EIC), and invasive cancer
without EIC). Furthermore, the associations between




The present study was approved by the ethics committee of
The First Affiliated Hospital with Nanjing Medical Univer-
sity. Written, informed consent was given by the patients
for their information to be used for research. This study
was also in compliance with the Helsinki Declaration.
From January 2010 to December 2011, operable breast
cancer patients, diagnosed with DCIS, invasive cancer
with EIC, and invasive cancer without EIC by using resec-
tion specimen, were screened in our hospital. The exclu-
sion criteria included the following: (a) patients treated
with neoadjuvant chemotherapy; (b) patients diagnosed
with breast cancer by using core biopsy; (c) not enough
specimens for further pathological analysis. At last, 167
consecutive breast cancer patients were recruited in this
study, including 47 DCIS cases, 62 cases diagnosed with
invasive cancer with EIC, and 58 cases diagnosed with
invasive cancer without EIC. Furthermore, specimens
of 21 benign breast diseases (mastopathy, hyperplasia,
and fibroadenoma in this study) were included in this
study.
Pathology
The pathology was reviewed by two experienced pa-
thologists independently. Disagreements were resolved
with consensus opinion. The specimens were paraffin-
embedded for histopathological examinations. Then,
4 μm histological sections were cut and stained with
hematoxylin and eosin (H&E). DCIS with microinva-
sion ≤ 1 mm was also considered as the DCIS category
in our study. EIC was defined as positive if the propor-
tion of DCIS was greater than 25 % of the whole tumor
in pathologic sections [13, 14].
Immunohistochemical (IHC) analyses on paraffin-
embedded material were used to determine the status ofestrogen receptor (ER), progesterone receptor (PR), Her2,
and Ki67. The status of ER, PR, Her2 and Ki67 were deter-
mined as described previously [15, 16]. Low Ki67 expres-
sion was defined as positive Ki67 staining ≤14 % in
pathologic sections, while high Ki67 expression was de-
fined as positive Ki67 staining >14 %. Patients with inva-
sive breast cancer were categorized into triple negative
and non-triple negative breast cancer in this study. Triple
negative breast cancer was defined as ER, PR and Her2
negative.
ALDH1 status was also determined by IHC. IHC
analyses were performed on 4 μm, formalin-fixed, paraffin-
embedded slides from breast cancer tissues. Paraffin-
embedded tissue sections were deparaffinized, rehydrated,
rinsed, and immersed in 10 mM sodium citrate (pH 6.0)
for antigen retrieval under high pressure in a pressure
cooker for 3 minutes. After treated with methanol contain-
ing 3 % hydrogen peroxide for 10 min to block endogenous
peroxidase activity, the slides were incubated with mouse
monoclonal antibody directed against human ALDH1
(aa 7–128, diluted 1:100; Becton, Dickinson and Com-
pany) for 1 hour at 37 °C. After washing, sequential in-
cubations were performed with horseradish peroxidase
(HRP) conjugated antibodies (Invitrogen) for 30 min at
room temperature. The stain was visualized using DAB
Plus (Dako) and hematoxylin counterstain. Tumor pre-
senting at least one ALDH1-positive cancer cell was
considered as an ALDH1-positive tumor, and stroma
presenting at least one ALDH1-positive stromal cell
was considered as an ALDH1-positive stroma [1, 6].
Statistical analysis
In our study, median, percentiles and range were analyzed
for continuous variables. The variables in this study in-
cluded: age at diagnose, pathology, tumor size, axillary
node status, tumor grade, ER, Her2, Ki67, and molecular
subtype. Differences between the subgroups with regard
to above variables were examined using Fisher’s exact test
or chi-square test. All P-values were two-tailed with 5 %
significance levels. All statistical analyses were performed




167 patients with different stages of breast cancer were
enrolled in the present study (Table 1), including 47 DCIS
cases, 62 cases diagnosed with invasive cancer with EIC,
and 58 cases diagnosed with invasive cancer without EIC.
The median patient age was 48 years (range, 20-82 years).
Of these 167 patients, 58 (34.7 %) were found with axillary
node involved, and 114 (68.3 %) were diagnosed with ER
positive breast cancer. Of 120 invasive cancer patients, 27
(22.5 %) were Her2 overexpressed.
Table 1 Characteristics of included breast cancer patients
Variables Number (%)
Age (y)
≤50 94 (56.3 %)
>50 73 (43.7 %)
Pathology
DCIS 47 (28.1 %)
Invasive cancer 120 (71.9 %)
Tumor sizea
≤2 cm 55 (45.8 %)
>2 cm 63 (52.5 %)
Not available 2 (1.7 %)
Axillary node status
Negative 103 (61.7 %)
Positive 58 (34.7 %)
Not available 6 (3.6 %)
ER status
Negative 53 (31.7 %)
Positive 114 (68.3 %)
Her2 statusa
Negative 93 (77.5 %)
Positive 27 (22.5 %)
aDCIS not included for analysis
Fig. 1 Immunohistochemical analyses of aldehyde dehydrogenase 1
(ALDH1) expression in benign breast disease (a), ductal carcinoma
in situ (b), and invasive breast cancer (c)
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ALDH1 protein expression was determined in benign
breast disease and breast cancer tissues. Of 21 benign
breast disease tissues, ALDH1 was only expressed in epi-
thelial cells in 3 cases; while ALDH1 was expressed in
tumor cells in 61.0 % (100/164, three cases not available)
of 164 breast cancer cases (Fig. 1). A significant differ-
ence was observed between these two groups (P < 0.001).
Additionally, ALDH1 was expressed in stromal cells in
89.5 % (17/19, two cases not available) of benign cases;
while ALDH1 was expressed in stromal cells in 92.0 %
(150/163, four cases not available) of 164 breast cancer
cases. There was no significant difference between these
two groups (P = 0.702).
ALDH1 expression in different stages of breast cancer
ALDH1 protein expression was determined in different
stages of breast cancer, including DCIS, invasive cancer
with EIC, and invasive cancer without EIC (Fig. 1).
ALDH1 was expressed in stromal cells in 93.5 % (43/46,
one case not available) of DCIS cases, 85.0 % (51/60,
two cases not available) of invasive cancer with EIC
cases, and 98.2 % (56/57, one case not available) of inva-
sive cancer without EIC cases. The ALDH1 expression
rates in stromal cells among these different stages ofbreast cancer were significantly different (P = 0.022,
Table 2).
Interestingly, ALDH1 was expressed in tumor cells in
41.3 % (19/46, one case not available) of DCIS cases,
45.0 % (27/60, two cases not available) of invasive cancer
with EIC cases, and 93.1 % (54/58) of invasive cancer
without EIC cases. A significant difference was observed
in these three groups (P < 0.001, Table 2).
Table 2 ALDH1 expression in different stages of breast cancer
Pathology Stromal ALDH1 Intratumoral ALDH1
Negative Positive P value Negative Positive P value
DCIS 3 43 0.022 27 19 <0.001
Invasive + EIC 9 51 33 27
Invasive 1 56 4 54
Table 4 Relationship between intratumoral ALDH1 expression
and clinicopathological parameters of invasive breast cancer
Variables Intratumoral ALDH1
Negative Positive P value
Age (y)
≤50 23 41 0.243
>50 14 40
Tumor size
≤2 cm 24 30 0.001
>2 cm 10 53
Grade
I-II 27 36 <0.001
III 4 35
Axillary node status
Negative 22 38 0.156
Positive 14 43
ER status
Negative 11 28 0.604
Positive 26 53
Her2 status
Negative 28 63 0.801
Positive 9 18
Ki67
≤14 % 15 21 0.009
Pan et al. Diagnostic Pathology  (2015) 10:66 Page 4 of 6Intratumoral ALDH1 expression in DCIS
The association between intratumoral ALDH1 expres-
sion and clinicopathological parameters of DCIS was
investigated (Table 3). In these 47 DCIS cases, no sig-
nificant association was observed between ALDH1
positivity and age (P = 0.528), tumor size (P = 0.951), grade
(P = 0.812), ER status (P = 0.428), Her2 status (P = 0.536),
or Ki67 (P = 0.667).
Intratumoral ALDH1 expression in invasive breast cancer
The relationship between intratumoral ALDH1 expres-
sion and clinicopathological parameters of invasive can-
cer was determined (Table 4). In these 120 invasive
cancer cases, no significant association was observed be-
tween ALDH1 positivity and age (P = 0.243). A signifi-
cantly higher rate (53/63) of intratumoral ALDH1
expression was observed in large tumors (> 2 cm) than
that (30/54) in small tumors (≤ 2 cm) (P = 0.001). There
was a trend that more intratumoral ALDH1 expressed inTable 3 Relationship between intratumoral ALDH1 expression
and clinicopathological parameters of DCIS
Variables Intratumoral ALDH1
Negative Positive P value
Age (y)
<40 5 5 0.528
≥40 22 14
Tumor size
≤1.5 cm 10 8 0.951
>1.5 cm 13 10
Grade
I-II 9 7 0.812
III 15 10
ER
Negative 7 7 0.428
Positive 20 12
Her2
Negative 14 11 0.536
Positive 8 4
Ki67
≤14 % 10 9 0.667
>14 % 9 6
>14 % 12 55
Molecular subtype
Triple negative 6 17 0.992
Non-triple negative 22 62tumors with involved lymph nodes (43/57) than that
without involved lymph nodes (38/60), but no significant
difference was observed (P = 0.156). Importantly, a signifi-
cantly higher rate (35/39) of intratumoral ALDH1 expres-
sion was observed in grade III tumors than that (36/63) in
grade I-II tumors (P < 0.001).
No significant association was observed between intratu-
moral ALDH1 positivity and ER status (P = 0.604), or Her2
status (P = 0.801). Similarly, the frequencies of intratumoral
ALDH1 positivity between triple negative and non-triple
negative breast cancers were not significantly different
(P = 0.992). The frequency of intratumoral ALDH1
positive tumors with high Ki67 expression was significantly
higher than that with low Ki67 expression (P = 0.009).
Intratumoral ALDH1 expression patterns of invasive and
in situ components of the same tumor
To determine if the difference seen in the expression of
some markers between invasive and in situ components
may reflect a potential divergence in expression associated
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examined the expression of ALDH1 in tumors with inva-
sive and in situ areas present on the same slides. Of 62 in-
vasive cancers with EIC cases, intratumoral ALDH1
expressions of both invasive and in situ components were
available in 48 cases. ALDH1 was expressed in 22 cases in
invasive component, and in 7 cases in the in situ compo-
nent. A significant difference was observed in these two
different components of the same tumor (P = 0.001). Of
these 48 cases, ALDH1 was expressed in both invasive
and in situ components in 7 cases. In these 7 cases, a
higher percentage of ALDH1 positive tumor cells were
observed in invasive component than that in the in situ
component in 4 cases.
Discussion
The purpose of the present study was to investigate
ALDH1 expression in cancer cells in human breast cancer
of different histologic stages. We found that ALDH1 was
expressed in tumor cells in DCIS cases with a lowest rate,
and in invasive cancer without EIC cases with a highest
rate. Importantly, intratumoral ALDH1 expression in in-
vasive component showed a higher rate of that in the in
situ component in the same tumor for the first time. Fur-
thermore, no significant association was observed between
ALDH1 positivity and clinicopathological parameters in
DCIS cases, while ALDH1 positive invasive breast cancers
were significantly more likely to be with large tumor size,
high grade, and high Ki67 expression.
In the present study, ALDH1 was expressed in tumor
cells in 41.3 % of DCIS cases, 45.0 % of invasive cancer
with EIC cases, and 93.1 % of invasive cancer without
EIC cases. Charafe-Jauffret and colleagues [8] have found
that ALDH1 was expressed in 34 % of inflammatory
breast cancer with approximately 3 %-5 % positively
stained cells in these tumors. However, Park and col-
leagues [9] have found that ALDH1 was expressed in
few cases (less than 10 %) and no significant difference
was observed in four histologic groups. To our know-
ledge, the difference of ALDH1 positivity in different
studies may be due to the different cutoffs. In the study
of Park [9], less than 10 % with ALDH1 stained was cat-
egorized as negative, while only 0 % was categorized as
negative in other studies [1, 6, 8, 12]. The previous study
[1] has shown that only 1 case was ALDH1 positive of
23 DCIS cases, while about 11 % invasive breast cancers
were ALDH1 positive. Similarly, the expression of
ALDH1 was lower in DCIS compared with IDC in our
study. Moreover, one of the most interesting findings of
our study is that intratumoral ALDH1 expression in in-
vasive component showed a higher rate of that in the in
situ component in the same tumor. All these findings
may potentially implicate ALDH1 in the progression to
invasion.Morimoto and colleagues [1] have found that ALDH1
positive breast cancers are significantly more likely to be
ER negative, PR negative, Her2 overexpression, and Ki67
positive, but ALDH1 is not significantly associated with
poor clinical outcomes. Charafe-Jauffret and colleagues
[8] have found that ALDH1 expression correlated with
tumor grade, but there was no correlation with other
clinical and pathologic features in inflammatory breast
cancer. Moreover, previous studies [6, 8] have reported
that ALDH1 is an independent prognostic marker to
predict poor patient outcome in breast cancer. In our
study, ALDH1 positive invasive breast cancers were sig-
nificantly more likely to be with large tumor size, high
grade, and high Ki67 expression, but no significant asso-
ciation was observed between ALDH1 positivity and
clinicopathological parameters in DCIS cases. All the
findings suggest ALDH1 positive cancer cells may be as-
sociated with aggressive phenotypes of breast cancer.
In this study, stromal ALDH1 positive cells were de-
tected in most cases, but the frequencies of stromal
ALDH1 positivity between benign breast disease and
breast cancer were not significantly different. It should
be pointed out that reports about human stromal stem
cell in benign terminal ductal-lobular unit are limited
[17–19]. Isfoss and colleagues [11] have described two
morphologically distinct stromal ALDH1 positive cell
types in benign mammary tissue from women with and
without breast cancer. The most numerous and widely
distributed stromal cell type is a spindle-shaped, fibrocyte-
like cell with slender cytoplasm and a small, elongated nu-
cleus, while the other ALDH1 positive stromal cell type
shows a round or oval shape, with a relatively large nu-
cleus. To the best of knowledge, the true identity of the
stromal ALDH1 positive cell types is unclear and needs to
be elucidated in future studies. In the present study, the
high frequencies of stromal ALDH1 positivity among dif-
ferent stages of breast cancer were significantly different.
Due to the small sample size, the difference may be attrib-
uted to chance. It seems that stromal ALDH1 expression
may be involved in different processes in carcinogenesis,
but future studies are needed.
Several limitations still exist in our study. First, the ex-
pression of ALDH1 in human breast cancer of different
histologic stages was focused on in this study, and the
prognosis of these cases was not available. Second, the
sample size was relative small, and our findings should
be confirmed in the future.
Conclusions
In conclusion, ALDH1 may play an important role in the
invasion of breast cancer, and may be associated with
aggressive phenotypes of breast cancer. Future studies
with large sample size should be needed to confirm our
findings.
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